Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Alexandra Drakaki
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Alexandra Drakaki
HS Associate Clinical Professor, Medicine. Authored (or co-authored) 103 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Allogene Therapeutics
- Links
- Sign up for this study
- ID
- NCT04696731
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- Expecting 120 study participants
- Last Updated